品牌分类
品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com
商品描述
BIOLOGICAL INFORMATION
DescriptionNeurotensin (8-13) is the smallest active fragment of neurotensin. Neurotensin(8-13) binds to the same sites as neurotensin. However, in the human brain, neurotensin(8-13) has a higher affinity for these sites than neurotensin does. The rapid degradation of neurotensin (NT) limits its clinical use in cancer imaging and therapy. Neurotensin(8–13) pseudopeptide, NT-VIII, was developed to sidestep this problem. Some changes were introduced to the sequence of neurotensin(8–13) to stabilize the molecule against enzymatic degradation: Arg8 is now N-methylated, and Lys and Tle have replaced Arg9 and Ile12, respectively. These have stabilized the molecule against enzymatic degradation without affecting its binding properties. Moreover, the increase in stability has enhanced tumor uptake, making this derivative a promising candidate for clinical use.
ApplicationMelanocortin
NoteFor research only, not for human use!
CHEMICAL INFORMATION
CAT No.ONP10595
CAS No.60482-95-3
NameNeurotensin (8-13)
Chemical NameNeurotensin-(8-13)
Purity≥98%
SynonymsNT(8-13)
FormulaC38H64N12O8
Molecular Weight816.99
One Letter CodeRRPYIL
Three Letter CodeARG-ARG-PRO-TYR-ILE-LEU
SMILESCCC(C)C(C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C2CCCN2C(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)N
InChI KeyDQDBCHHEIKQPJD-CSJNAZMVSA-N
SourceSynthetic
FormDry Powder
ColorWhite
SolubilityN/A
SHIPPING & STORAGE
Storage4 degree ℃ for short term (weeks) and -20 degree ℃ for long term.
ShippingIce Pack
Stability≥ 2 years
REFERENCES & CITATIONS
1.Hadden MK, et al. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology. Dec 2005; 49(8): 1149-1159.
2.Kokko KP, et al. In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier. Neuropharmacology. Mar 2005; 48(3): 417-425.
3.Sotty, F. et al. Neurosci. 98, 485 (2000)
DOCUMENTATIONS
- COA
- Data sheet
- MS
- RP-HPLC
- MSDS
- Handling Instruction
PROMOTIONS & EVENTS
